We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213109
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 21, 2006
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.

Brief Summary:
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: Miglitol Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

Drug Information available for: Miglitol
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type1 Diabetes
  • Criteria of postprandial glucose and HbA1c are met

Exclusion Criteria:

  • Type2 Diabetes
  • Patients with antidiabetic drugs
  • The other exclusion criteria are met

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213109

Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Ibaraki, Japan
Kanagawa, Japan
Kumamoto, Japan
Oita, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Study Director: Clinical Promotion Group Sanwa Kagaku Kenkyusho Co., Ltd.

ClinicalTrials.gov Identifier: NCT00213109     History of Changes
Other Study ID Numbers: MG1006
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 21, 2006
Last Verified: September 2006

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors